Piroxicam is an NSAID used to treat the symptoms of osteoarthritis and rheumatoid arthritis. Its long half-life enables it to be administered once daily.
- Mechanism
- Curator reviewed
The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
- Primary indication
- For treatment of osteoarthritis and rheumatoid arthritis.Curator reviewed · 3 structured indications
- Formula / weight
- C15H13N3O4S · 331.346 g/mol (avg)
- First approval
- Canada, 1995 · United States, 1993
- Also known as
- Piroxicam betadex · Pyroxycam
- Code names
- CP-16,171
- Brand names
Resolves to
QYSPLQLAKJAUJT-UHFFFAOYSA-NSMILESCN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Piroxicam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account